Identification of potential biomarkers of triton WR-1339 induced hyperlipidemia: NMR-based plasma metabolomics approach and gene expression analysis.

BACKGROUND

Hyperlipidemia is a complex lipid metabolism disorder defined as an abnormal increase in circulating levels of one or more plasma lipids and lipoproteins. Triton WR-1339-induced hyperlipidemia model is one of the most commonly used acute models for hyperlipidemia induction in research. However, the metabolic alteration induced by Triton WR-1339 remains unclear.

AIMS

This study aimed to identify potential biomarkers associated with the Triton WR-1339-induced hyperlipidemia model. In addition, it aims to explore the underlying mechanisms of metabolic disturbances associated with hyperlipidemia.

METHODS

Male Wistar rats were administered Triton WR-1339 to induce hyperlipidemia. Plasma samples were collected for lipid assays and for metabolomics analysis using nuclear magnetic resonance spectroscopy. Gene expression in liver, cardiac, and kidney tissues of key associated transporters including SLC16A1, SLC25A10, SLC5A3, and SLC7A8 and SDHA enzyme subunit was assessed using RT-PCR. In-silico analysis complemented experimental data using NEBION Genevestigator and STITCH databases for molecular interactions.

RESULTS

Triton WR-1339 administration significantly elevated plasma triglycerides. Orthogonal partial least squares-discriminant analysis (OPLS-DA) demonstrated distinct metabolic profiles between control and model groups. Metabolomics results identified potential biomarkers (p < 0.05), including myo-inositol, succinate, creatine, glycine, serine, isoleucine and creatine phosphate, which all showed higher levels in hyperlipidemia group compared to control group while xanthine showed lower levels in hyperlipidemia group. Potential biomarkers were associated with inflammatory, oxidative stress responses, and abnormal lipid metabolism. Gene expression analysis revealed significant tissue-specific alterations including changes in the expression of SDHA in the liver, an upregulated SLC16A1 in cardiac tissue (in-silico and in-vivo), a downregulated SLC5A3 in cardiac tissue (in-vivo), an upregulated SLC25A10 in cardiac tissue (in-vivo) and differential in-silico expression of SLC25A10 across liver and kidney tissues. Further network analysis indicates that Triton WR-1339 may induce hyperlipidemia by significantly elevating triglyceride levels through the inhibition of LPL.

CONCLUSIONS

Our findings identify a set of metabolites as potential biomarkers of hyperlipidemia development in the Triton WR-1339 model. Correlation between gene expression analysis and metabolic profiling results demonstrates a possible mechanism in which Triton WR-1339 leads to metabolic disruption during hyperlipidemia induction.